Fusion protein and use thereof
AssigneeChigenovo Co., Ltd
InventorsShaohong Chen, Tianyong Shi, Dandan Hao, Saichao He, Linlin NIU
Life of this patent
Estimating the term…
Loading patent…
AssigneeChigenovo Co., Ltd
InventorsShaohong Chen, Tianyong Shi, Dandan Hao, Saichao He, Linlin NIU
Estimating the term…
The present application relates to a fusion protein and use thereof. The fusion protein comprises RdCVF and a signal peptide, wherein the signal peptide is an amino acid sequence set forth in any one of SEQ ID NOs: 27-31 and 33. The present application also relates to an isolated nucleic acid molecule comprising a) a polynucleotide encoding RdCVF and b) a polynucleotide encoding a signal peptide. The present application also provides a vector, a cell, and a pharmaceutical composition containing the nucleic acid molecule, as well as medical use thereof. The fusion protein and/or isolated nucleic acid molecule described herein can effectively increase the secretion of RdCVF.
A fusion protein comprising RdCVF and a signal peptide, wherein the signal peptide is an amino acid sequence set forth in any one of SEQ ID NOs:
3-4. (canceled)
6-7. (canceled)
(canceled)
An isolated nucleic acid molecule, comprising a) a polynucleotide encoding RdCVF and b) a polynucleotide encoding a signal peptide.
13-16. (canceled)
18-20. (canceled)
22-25. (canceled)
27-30. (canceled)
32-38. (canceled)
40-43. (canceled)
45-46. (canceled)
49-51. (canceled)
A method of increasing the expression level of RdCVF, comprising the step of making a nucleic acid molecule capable of encoding RdCVF to contain a polynucleotide encoding a signal peptide.
56-58. (canceled)
(canceled)
63-93. (canceled)
Dependencies are inferred from the claim text.